Stem Cell Clinic

CorMedix Inc. Announces Outpatient Availability of DefenCath

By Embryonic Stem Cells

BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath® (taurolidine and heparin) to outpatient dialysis centers and vascular access clinics where patients receive outpatient dialysis and catheter placement services. The outpatient launch coincides with the effective date of July 1st for outpatient reimbursement of DefenCath as directed by the Center for Medicare & Medicaid Services (CMS).

Go here to see the original:
CorMedix Inc. Announces Outpatient Availability of DefenCath

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

By Embryonic Stem Cells

Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need

Originally posted here:
Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Embryonic Stem Cells

WESTLAKE VILLAGE, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 325,000 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 55,000 shares of Arcutis’ common stock to 43 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of July 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

Read the rest here:
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Spectral AI Expands Clinical Trial Sites for Pivotal U.S. Burn Study

By Global News Feed

DALLAS, July 03, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has added two new U.S. Clinical Trial Sites for its 2024 Burn Pivotal Study: the University of California San Diego and the University of Utah.

See the rest here:
Spectral AI Expands Clinical Trial Sites for Pivotal U.S. Burn Study

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

By Global News Feed

OCALA, Fla., July 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provided an update on the Phase 1b/2 “DURIPANC” study of Ampligen and AstraZeneca’s Imfinzi as a combination therapy for late-stage pancreatic cancer. The Company also provided a business update, including that as a result of recent financings, AIM recently had stockholders’ equity of $6.9 million.

Visit link:
AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society…

By Global News Feed

Multiple studies confirm ART12.11’s superior advantages as a product candidate for the treatment of anxiety related disorders Multiple studies confirm ART12.11’s superior advantages as a product candidate for the treatment of anxiety related disorders

Follow this link:
Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society...

Rafarma pharmaceutical updates: creation of a joint research and production enterprise in Busan (South Korea) between Rafarma and the Korean…

By Global News Feed

Sheridan, Wyoming, USA, July 03, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - Rafarma Pharmaceuticals is pleased to announce the signing of a preliminary agreement to establish a joint industrial venture in Busan Technology Park (South Korea) as the Dongnam Industrial Park of Radiological & Medical Sciences. The partners in the venture are Rafarma and the Korean pharmaceutical company Woods Medical Care.

Read this article:
Rafarma pharmaceutical updates: creation of a joint research and production enterprise in Busan (South Korea) between Rafarma and the Korean...

→←